CEO Total Pay
$10.4M
FY2025 Summary Compensation, above median
The CEO earned $10.4M in FY2025 against median worker pay of $434,769 · Chemicals & Pharmaceuticals.
Data updated August 2026
Subscribe to Mirum Pharmaceuticals, Inc. CEO pay filing updates (RSS)
Answer first
According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $434,769. Industry placement uses the FY2025 SIC-28 peer cohort (# 116 of 168, 32nd percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
Mirum Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing
Total CEO compensation, the full national distribution, this company marked
$10,441,224 Top 36% higher than 64% of 1,423 companies
Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025
CEO total pay ($10.4M) against pay ratio (24:1) for Mirum Pharmaceuticals, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
A component-level pay breakdown is not reported in Mirum Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2024 | $6.6M | - | $393,477 | 17:1 | - |
| 2025 | $10.4M | +58% | $434,769 | 24:1 | +7:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1759425, FY2024–2025. Adjacent-year deltas only.
Mirum Pharmaceuticals, Inc.'s FY2025 ratio 24:1 ranks #116 of 168 Chemicals & Pharmaceuticals filers (32nd percentile). the CEO earned 24× the median employee ($434,769) in FY2025.
At $434,769 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.
CEO Total Pay
$10.4M
FY2025 Summary Compensation, above median
Pay Ratio
24:1
Below typical
Mirum Pharmaceuticals, Inc.'s FY2025 ratio 24:1 ranks #116 of 168 Chemicals & Pharmaceuticals filers (32nd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Mirum Pharmaceuticals, Inc.'s $10.4M CEO total is above the $7.9M industry median CEO pay.
Dollar rank #506 and ratio rank #1180 split - treat 24:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.
Read our methodology - how this data is sourced, computed, and verified. Mirum Pharmaceuticals, Inc.'s FY2025 ratio 24:1 ranks #116 of 168 Chemicals & Pharmaceuticals filers (32nd percentile).
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.
ABS(ceo_total_comp) peer at $10.4M (Δ $18K lighter vs Mirum Pharmaceuticals, Inc.); STEEP · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
ABS(ceo_total_comp) peer at $10.5M (Δ $18K heavier vs Mirum Pharmaceuticals, Inc.); MEGA · LOW-MED vs this page's FLOOR · HEAVY · ELITE-MED.
ABS(ceo_total_comp) peer at $10.5M (Δ $28K heavier vs Mirum Pharmaceuticals, Inc.); STEEP · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
ABS(ceo_total_comp) peer at $10.5M (Δ $39K heavier vs Mirum Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Vir Biotechnology, Inc. stamps FLOOR · HEAVY nearest in-SIC by ABS(pay_ratio) to Mirum Pharmaceuticals, Inc.'s FLOOR filing.
Mirum Pharmaceuticals, Inc.'s FY2025 package sits #506 by CEO dollars and #1180 by ratio under HEAVY · FLOOR.
Mirum Pharmaceuticals, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.